Welcome to our dedicated page for Evotec news (Ticker: EVO), a resource for investors and traders seeking the latest updates and insights on Evotec stock.
Evotec AG (EVO) delivers cutting-edge solutions in drug discovery and development through strategic partnerships across the life sciences sector. This news hub provides investors and industry professionals with essential updates on the company’s progress in transforming biomedical research into therapeutic solutions.
Access real-time information on quarterly financial results, R&D collaborations, and manufacturing advancements from Evotec’s biologics division. Our curated collection includes updates on central nervous system research, oncology developments, and precision medicine initiatives that demonstrate the company’s leadership in pharmaceutical innovation.
Key updates cover regulatory milestones, technology platform enhancements, and global expansion efforts across Evotec’s European and U.S. facilities. Stay informed about partnerships driving novel therapies in metabolic diseases, infectious disease treatments, and next-generation biologics production.
Bookmark this page for streamlined access to Evotec’s latest achievements in bridging academic research-commercialization gap. Regularly updated content ensures you maintain strategic awareness of developments impacting the drug discovery ecosystem.
Evotec SE (NASDAQ: EVO) has secured a $2.5 million grant from The Gates Foundation to advance the development of next-generation tuberculosis (TB) treatment regimens. This marks the second grant from the foundation focused on evaluating improved TB therapies using Evotec's translational platforms.
The new funding extends a successful five-year partnership that has already produced standardized preclinical data for selecting shorter, safer, and more effective TB drug combinations. Evotec will utilize its integrated TB platform to further characterize promising treatment regimens, aiming to accelerate the development of transformative TB treatments.
Evotec SE has scheduled the announcement of its first quarter 2025 financial results for Tuesday, May 6, 2025. The company will host a conference call and webcast to discuss the quarterly performance and provide business updates.
The event details include:
- Date: Tuesday, May 6, 2025
- Time: 2:00 PM CEST (1:00 PM BST, 8:00 AM EDT)
- Format: Audio webcast with presentation slides
- Language: English
Participants can join via web or phone, with pre-registration required for dial-in access. The presentation will be available simultaneously for phone participants, and an on-demand version will be accessible through Evotec's website under Financial Publications.
Evotec SE (NASDAQ:EVO) has announced significant progress in its strategic research collaboration with Bristol Myers Squibb, triggering total payments of US$ 75 million to Evotec through performance-based and program-based achievements.
The collaboration, initiated in 2018 and expanded in 2022, combines Evotec's high-performance multi-omics screening and AI-supported data analytics with Bristol Myers Squibb's cereblon E3 ligase modulators (CELMoDs™) library. The partnership focuses on developing molecular glue degraders for high-value targets in oncology and other therapeutic areas.
The collaboration continues to advance its pipeline of molecular degraders, aiming to deliver multiple first-in-class products to market for unmet medical needs.
Evotec SE (NASDAQ:EVO) has announced its FY 2024 results and unveiled a new strategic direction focused on drug discovery and biologics. The company reported a 2% revenue increase to €797.0 million, with Q4 2024 revenues up 10% to €221.2 million.
Key highlights include:
- Just - Evotec Biologics segment grew 71% year-over-year to €185.6 million
- Adjusted Group EBITDA reached €22.6 million
- Priority Reset program on track to deliver €40 million in annual savings
- Net debt leverage ratio improved to 1.9x
For 2025 guidance, Evotec expects:
- Revenue range of €840-880 million
- R&D expenditure of €40-50 million
- Adjusted Group EBITDA of €30-50 million
The company's 2028 outlook targets revenue CAGR of 8-12% (2024-2028) and adjusted EBITDA margin above 20%.
Evotec SE (NASDAQ: EVO) has scheduled the announcement of its financial year 2024 results for Thursday, April 17, 2025. The company will host a conference call at 2:00 PM CEST (1:00 PM BST, 8:00 AM ET) to discuss the results and provide updates on their concluded strategic review process.
The presentation will be conducted in English and will be accessible via both webcast and phone conference. Participants joining via phone must pre-register to receive dedicated dial-in details. The company will make an on-demand version of the webcast available on their website following the presentation.
Evotec SE (NASDAQ:EVO) has achieved a significant milestone in its neuroscience collaboration with Bristol Myers Squibb, triggering a $20 million research payment. The achievement relates to advancing a promising pre-clinical programme in neurodegeneration.
The strategic partnership, initiated in December 2016, focuses on developing disease-modifying treatments for neurodegenerative diseases, moving beyond current symptom management approaches. Notable successes include the in-licensing of EVT8683 (now BMS-986419) by Bristol Myers Squibb in September 2021.
In March 2023, both companies extended their collaboration for an additional eight years, demonstrating their commitment to developing breakthrough therapies for neurological diseases.
Evotec SE (NASDAQ:EVO) announced a significant leadership change as Chief Financial Officer Laetitia Rouxel will step down effective February 28, 2025, and leave the company by March 31, 2025. Paul Hitchin has been appointed as the new CFO, effective March 1, 2025.
Hitchin brings over 20 years of finance leadership experience, most recently serving as CFO at Mediq where he led business growth and transformation initiatives. His previous roles include 13 years at General Electric, including 5 years with GE Healthcare. The company emphasized that Hitchin's financial expertise and transformation experience will be important for Evotec's strategic journey toward profitable and sustainable growth.
Evotec SE (NASDAQ: EVO) announced a collaborative grant of US$ 4.5 million from the Korea Institute of Advanced Technology (KIAT) alongside Yonsei University and Korean biotech Zymedi. The funding will support the development of first-in-class biologic therapies for lung diseases, specifically asthma and idiopathic pulmonary fibrosis (IPF).
The project focuses on developing novel anti-inflammatory and anti-fibrotic antibodies targeting tRNA synthetases, an emerging therapeutic target class. The collaboration combines Yonsei University's expertise in tRNA synthetases, Zymedi's translational capabilities, and Evotec's antibody development and manufacturing technologies.
The initiative aims to advance first-in-class antibodies with a novel mechanism-of-action to treat IPF and non-type 2 asthma, both conditions with significant unmet medical needs.
Evotec SE and Novo Nordisk have selected their first three projects for LAB eN² drug discovery accelerator, focusing on cardiometabolic diseases. The selected projects come from Boston University, Harvard University (with Mass General Brigham), and Joslin Diabetes Center. The program is also expanding to include five new academic institutions.
The projects focus on: inflammation in cardiometabolic diseases and chronic kidney disease; molecular mechanisms related to bariatric surgery for metabolic syndrome treatment; and a novel target approach for type 1 diabetes. Projects receive initial Discovery Award funding, with potential additional funding up to IND application stage. Novo Nordisk maintains the option to further develop and license specific programs.
FAQ
What is the current stock price of Evotec (EVO)?
What is the market cap of Evotec (EVO)?
